SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "(WFRF:(Aldrin Anders)) "

Search: (WFRF:(Aldrin Anders))

  • Result 1-6 of 6
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  • Liwing, Johan, et al. (author)
  • Improved survival in myeloma patients : starting to close in on the gap between elderly patients and a matched normal population
  • 2014
  • In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 164:5, s. 684-693
  • Journal article (peer-reviewed)abstract
    • The outcome for multiple myeloma patients has improved since the introduction of bortezomib, thalidomide and lenalidomide. However, studies comparing new and conventional treatment include selected patient groups. We investigated consecutive patients (n = 1638) diagnosed in a defined period and compared survival with a gender- and age-matched cohort Swedish population (n = 9 340 682). Median overall survival for non-high-dose treated patients was 2.8 years. The use of bortezomib, thalidomide or lenalidomide in first line therapy predicted a significantly longer overall survival (median 4.9 years) compared to conventional treatment (2.3 years). Among non-high-dose treated patients receiving at least 2 lines with bortezomib, thalidomide or lenalidomide, 69% and 63% have survived at 3 and 5 years as compared to 48% and 22% with conventional drugs and 88% and 79% in the matched cohort populations, respectively. The median overall survival in high-dose treated patients was 6.9 years. Of these patients, 84% survived at 3 years and 70% at 5 years as compared to 98% and 95% in the matched cohort population. Overall survival in the best non-high-dose treated outcome group is closing the gap with the matched cohort. Upfront use of new drugs is clearly better than waiting until later lines of treatment.
  •  
5.
  •  
6.
  • Norin, Stefan, et al. (author)
  • Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
  • 2015
  • In: Leukemia Research. - : Elsevier. - 0145-2126 .- 1873-5835. ; 39:1, s. 33-37
  • Journal article (peer-reviewed)abstract
    • There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-6 of 6
Type of publication
journal article (4)
other publication (2)
Type of content
peer-reviewed (5)
other academic/artistic (1)
Author/Editor
Svensson, Magnus (2)
Johansson, Peter (2)
Carlson, Kristina (2)
Näsman, Per (2)
Zhang, Yan (1)
Korhonen, Laura (1)
show more...
Lindholm, Dan (1)
Vertessy, Beata G. (1)
Wang, Mei (1)
Wang, Xin (1)
Liu, Yang (1)
Kumar, Rakesh (1)
Wang, Dong (1)
Li, Ke (1)
Liu, Ke (1)
Zhang, Yang (1)
Nàgy, Péter (1)
Kominami, Eiki (1)
van der Goot, F. Gis ... (1)
Bonaldo, Paolo (1)
Thum, Thomas (1)
Adams, Christopher M (1)
Minucci, Saverio (1)
Vellenga, Edo (1)
Swärd, Karl (1)
Nilsson, Per (1)
De Milito, Angelo (1)
Zhang, Jian (1)
Shukla, Deepak (1)
Kågedal, Katarina (1)
Chen, Guoqiang (1)
Liu, Wei (1)
Cheetham, Michael E. (1)
Sigurdson, Christina ... (1)
Clarke, Robert (1)
Zhang, Fan (1)
Gonzalez-Alegre, Ped ... (1)
Jin, Lei (1)
Chen, Qi (1)
Taylor, Mark J. (1)
Romani, Luigina (1)
Wang, Ying (1)
Kumar, Ashok (1)
Holmgren, Anders (1)
Simons, Matias (1)
Ishaq, Mohammad (1)
Yang, Qian (1)
Algül, Hana (1)
Brest, Patrick (1)
Simon, Hans-Uwe (1)
show less...
University
Umeå University (4)
Karolinska Institutet (4)
Royal Institute of Technology (2)
Uppsala University (2)
Linköping University (2)
Stockholm University (1)
show more...
Lund University (1)
University of Borås (1)
Swedish University of Agricultural Sciences (1)
show less...
Language
English (4)
Swedish (2)
Research subject (UKÄ/SCB)
Medical and Health Sciences (4)
Social Sciences (2)
Humanities (2)
Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view